Literature DB >> 18230059

Toll-like receptor polymorphisms and susceptibility to human disease.

E Ann Misch1, Thomas R Hawn.   

Abstract

Although several lines of evidence suggest that variation in human inflammation is genetically controlled, the genes which regulate these responses are largely unknown. TLRs (Toll-like receptors) mediate recognition of microbes, regulate activation of the innate immune response and influence the formation of adaptive immunity. Cellular and molecular studies over the past several years have identified a number of common TLR polymorphisms that modify the cellular immune response and production of cytokines in vitro. In addition, human genetic studies suggest that some of these polymorphisms are associated with susceptibility to a spectrum of diseases. In this review, we summarize studies of common TLR polymorphisms and how this work is beginning to illuminate the influence of human variation on inflammation and disease susceptibility.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230059     DOI: 10.1042/CS20070214

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  102 in total

1.  Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis.

Authors:  Javeed A Shah; Jay C Vary; Tran T H Chau; Nguyen D Bang; Nguyen T B Yen; Jeremy J Farrar; Sarah J Dunstan; Thomas R Hawn
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

Review 2.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 3.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 4.  Leprosy as a genetic disease.

Authors:  Andrea Alter; Audrey Grant; Laurent Abel; Alexandre Alcaïs; Erwin Schurr
Journal:  Mamm Genome       Date:  2010-10-09       Impact factor: 2.957

Review 5.  Structural insights into the assembly of large oligomeric signalosomes in the Toll-like receptor-interleukin-1 receptor superfamily.

Authors:  Ryan Ferrao; Jixi Li; Elisa Bergamin; Hao Wu
Journal:  Sci Signal       Date:  2012-05-29       Impact factor: 8.192

Review 6.  Possible evidence of systemic lupus erythematosus and periodontal disease association mediated by Toll-like receptors 2 and 4.

Authors:  C P C Marques; Y Maor; M S de Andrade; V P Rodrigues; B B Benatti
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

Review 7.  Inflammation in obesity-related diseases.

Authors:  Robert W O'Rourke
Journal:  Surgery       Date:  2008-10-30       Impact factor: 3.982

8.  Association of VDR gene polymorphisms and 22 bp deletions in the promoter region of TLR2Δ22 (-196-174) with increased risk of pulmonary tuberculosis: A case-control study in tea garden communities of Assam.

Authors:  Kangjam Rekha Devi; Kaustab Mukherjee; Pradipta Kumar Chelleng; Simanta Kalita; Upasana Das; Kanwar Narain
Journal:  J Clin Lab Anal       Date:  2018-05-04       Impact factor: 2.352

9.  Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans.

Authors:  Digna Rosa Velez; Christian Wejse; Martin E Stryjewski; Eduardo Abbate; William F Hulme; Jamie L Myers; Rosa Estevan; Sara G Patillo; Rikke Olesen; Alessandra Tacconelli; Giorgio Sirugo; John R Gilbert; Carol D Hamilton; William K Scott
Journal:  Hum Genet       Date:  2009-09-22       Impact factor: 4.132

10.  European wild boars and domestic pigs display different polymorphic patterns in the Toll-like receptor (TLR) 1, TLR2, and TLR6 genes.

Authors:  Ingrid-Maria Bergman; Johan K Rosengren; Kjell Edman; Inger Edfors
Journal:  Immunogenetics       Date:  2009-12-02       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.